scholarly journals Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Liang Xia ◽  
Han-Shuo Zhang ◽  
Jing Bao ◽  
Yu-Chen Zhao ◽  
Hai-Long Xia
Keyword(s):  
Epstein Barr Virus ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
Successful Outcome ◽  
Salvage Regimen ◽  
Therapy Regimen ◽  
Barr Virus ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Epstein Barr

Epstein-Barr virus (EBV)-associated lymph nodal T/NK cell lymphoma (nodal TNKL) is a rare and aggressive malignancy with an extremely poor prognosis. Although treatments of extranodal NK/T cell lymphoma are frequently reported, the characteristics and pathogenesis of EBV-associated nodal TNKL are different. However, there is no known effective therapy regimen at present. Here, we reported the clinical efficacy and feasibility of the programmed death 1 (PD-1) blockade therapy regimen in an elderly female patient with EBV-associated nodal TNKL. The patient failed to respond to cyclophosphamide, doxorubicin, vindesine, and prednisone regimen but achieved complete response after three cycles of anti-PD-1 antibody (tislelizumab) combined with gemcitabine and oxaliplatin (GemOx) regimen. The finding indicated that tislelizumab combined with the GemOx regimen may be a potent salvage regimen for EBV-associated nodal TNKL.

scholarly journals Programmed death 1 is highly expressed on CD8+CD57+T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus

Immunology ◽  
2017 ◽  
Vol 152 (4) ◽  
pp. 660-676 ◽  
Author(s):  
Maria T. Cencioni ◽  
Roberta Magliozzi ◽  
Richard Nicholas ◽  
Rehiana Ali ◽  
Omar Malik ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cells ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Cytotoxic Response ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Epstein Barr

Epstein-Barr Virus-Infected Malignant T/NK-Cell Lymphoma in a Patient with Hypersensitivity to Mosquito Bites

2004 ◽  
Vol 12 (3) ◽  
pp. 265-272 ◽  
Author(s):  
Satoru Kase ◽  
Hironobu Adachi ◽  
Mitsuhiko Osaki ◽  
Masanao Murakami ◽  
Takeshi Sairenji ◽  
...  
Keyword(s):  
Epstein Barr Virus ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
Barr Virus ◽  
Epstein Barr

Epstein-Barr virus–positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features

2015 ◽  
Vol 46 (7) ◽  
pp. 981-990 ◽  
Author(s):  
Yoon Kyung Jeon ◽  
Jo-Heon Kim ◽  
Ji-Youn Sung ◽  
Jae Ho Han ◽  
Young-Hyeh Ko
Keyword(s):  
Epstein Barr Virus ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
Clinicopathological Features ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Upregulation of Interleukin 7 Receptor Alpha and Programmed Death 1 Marks an Epitope-Specific CD8+ T-Cell Response That Disappears following Primary Epstein-Barr Virus Infection

2009 ◽  
Vol 83 (18) ◽  
pp. 9068-9078 ◽  
Author(s):  
Delphine Sauce ◽  
Martin Larsen ◽  
Rachel J. M. Abbott ◽  
Andrew D. Hislop ◽  
Alison M. Leese ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Response ◽  
Epstein Barr Virus ◽  
T Cell Response ◽  
Receptor Alpha ◽  
Barr Virus ◽  
Interleukin 7 ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Epstein Barr

ABSTRACT In immunocompetent individuals, the stability of the herpesvirus-host balance limits opportunities to study the disappearance of a virus-specific CD8+ T-cell response. However, we noticed that in HLA-A*0201-positive infectious mononucleosis (IM) patients undergoing primary Epstein-Barr virus (EBV) infection, the initial CD8 response targets three EBV lytic antigen-derived epitopes, YVLDHLIVV (YVL), GLCTLVAML (GLC), and TLDYKPLSV (TLD), but only the YVL and GLC reactivities persist long-term; the TLD response disappears within 10 to 27 months. While present, TLD-specific cells remained largely indistinguishable from YVL and GLC reactivities in many phenotypic and functional respects but showed unique temporal changes in two markers of T-cell fate, interleukin 7 receptor alpha (IL-7Rα; CD127) and programmed death 1 (PD-1). Thus, following the antigen-driven downregulation of IL-7Rα seen on all populations in acute IM, in every case, the TLD-specific population recovered expression unusually quickly post-IM. As well, in four of six patients studied, TLD-specific cells showed very strong PD-1 upregulation in the last blood sample obtained before the cells’ disappearance. Our data suggest that the disappearance of this individual epitope reactivity from an otherwise stable EBV-specific response (i) reflects a selective loss of cognate antigen restimulation (rather than of IL-7-dependent signals) and (ii) is immediately preceded, and perhaps mediated, by PD-1 upregulation to unprecedented levels.

scholarly journals EBV microRNA-BHRF1-2-5p targets the 3′UTR of immune checkpoint ligands PD-L1 and PD-L2

Blood ◽  
2019 ◽  
Vol 134 (25) ◽  
pp. 2261-2270 ◽  
Author(s):  
Alexandre S. Cristino ◽  
Jamie Nourse ◽  
Rachael A. West ◽  
Muhammed Bilal Sabdia ◽  
Soi C. Law ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Epstein Barr Virus ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Barr Virus ◽  
Large B Cell Lymphoma ◽  
Programmed Death ◽  
Epstein Barr ◽  
Fine Tune ◽  
Large B Cell

This article reports a novel mechanism by which Epstein-Barr virus (EBV) microRNA (miRNA) plays a role to fine-tune the expression of LMP1-driven amplification of inhibitory checkpoint programmed death ligand 1 (PD-L1) and PD-L2 in EBV+ diffuse large B-cell lymphoma. Identification and understanding of the immune checkpoint regulation via miRNA may enable potential novel RNA-based therapies to emerge.

Sign in / Sign up

Export Citation Format

Share Document